CRISPR THERAPEUTICS AG Income (Loss) from Equity Method Investments
CRISPR THERAPEUTICS AG (CRSP) reported Income (Loss) from Equity Method Investments of -$5.47 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-02-15.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2022-02-15
- CRISPR THERAPEUTICS AG income (loss) from equity method investments for the quarter ending 2019-12-31 was $0.00.
- CRISPR THERAPEUTICS AG income (loss) from equity method investments for the quarter ending 2019-09-30 was -$3.43M.
- CRISPR THERAPEUTICS AG income (loss) from equity method investments for the quarter ending 2019-06-30 was -$1.01M.
- CRISPR THERAPEUTICS AG income (loss) from equity method investments for the quarter ending 2019-03-31 was -$1.02M.
- CRISPR THERAPEUTICS AG income (loss) from equity method investments for fiscal 2019 was -$5.47M.
- CRISPR THERAPEUTICS AG income (loss) from equity method investments for fiscal 2018 was -$4.28M.
- CRISPR THERAPEUTICS AG income (loss) from equity method investments for fiscal 2017 was -$1.76M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month | Income (Loss) from Equity Method Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$3.43M derived: sum of 2 quarters · filed 2022-02-15 | -$4.44M derived: sum of 3 quarters · filed 2022-02-15 | -$5.47M 10-K · filed 2022-02-15 | |
| 2019-09-30 | -$3.43M 10-Q · filed 2020-10-28 | -$4.44M derived: sum of 2 quarters · filed 2020-10-28 | -$5.47M 10-Q · filed 2020-10-28 | -$6.49M derived: sum of 4 quarters · filed 2021-02-16 | |
| 2019-06-30 | -$1.01M 10-Q · filed 2020-07-27 | -$2.04M 10-Q · filed 2020-07-27 | -$3.06M derived: sum of 3 quarters · filed 2021-02-16 | -$4.07M derived: sum of 4 quarters · filed 2021-02-16 | |
| 2019-03-31 | -$1.02M 10-Q · filed 2020-04-28 | -$2.04M derived: sum of 2 quarters · filed 2021-02-16 | -$3.06M derived: sum of 3 quarters · filed 2021-02-16 | -$4.21M derived: sum of 4 quarters · filed 2021-02-16 | |
| 2018-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | -$2.03M derived: sum of 2 quarters · filed 2021-02-16 | -$3.18M derived: sum of 3 quarters · filed 2021-02-16 | -$4.28M 10-K · filed 2021-02-16 | |
| 2018-09-30 | -$1.01M 10-Q · filed 2019-10-28 | -$2.17M derived: sum of 2 quarters · filed 2019-10-28 | -$3.26M 10-Q · filed 2019-10-28 | -$3.71M derived: sum of 4 quarters · filed 2020-02-12 | |
| 2018-06-30 | -$1.15M 10-Q · filed 2019-07-29 | -$2.24M 10-Q · filed 2019-07-29 | -$2.70M derived: sum of 3 quarters · filed 2020-02-12 | -$3.06M derived: sum of 4 quarters · filed 2020-02-12 | |
| 2018-03-31 | -$1.09M 10-Q · filed 2019-04-29 | -$1.54M derived: sum of 2 quarters · filed 2020-02-12 | -$1.90M derived: sum of 3 quarters · filed 2020-02-12 | -$2.41M derived: sum of 4 quarters · filed 2020-02-12 | |
| 2017-12-31 | -$453.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | -$812.00K derived: sum of 2 quarters · filed 2020-02-12 | -$1.32M derived: sum of 3 quarters · filed 2020-02-12 | -$1.76M 10-K · filed 2020-02-12 | |
| 2017-09-30 | -$359.00K 10-Q · filed 2018-11-07 | -$864.00K derived: sum of 2 quarters · filed 2018-11-07 | -$1.31M 10-Q · filed 2018-11-07 | -$37.12M derived: sum of 4 quarters · filed 2020-10-28 | |
| 2017-06-30 | -$505.00K 10-Q · filed 2018-08-07 | -$951.00K 10-Q · filed 2018-08-07 | -$36.77M derived: sum of 3 quarters · filed 2020-10-28 | -$36.77M derived: sum of 4 quarters · filed 2020-10-28 | |
| 2017-03-31 | -$446.00K 10-Q · filed 2018-05-08 | -$36.26M derived: sum of 2 quarters · filed 2020-10-28 | -$36.26M derived: sum of 3 quarters · filed 2020-10-28 | -$36.95M derived: sum of 4 quarters · filed 2020-10-28 | |
| 2016-12-31 | -$35.81M derived: 10-Q 12 month − 10-Q 9 month · filed 2020-10-28 | -$35.81M derived: sum of 2 quarters · filed 2020-10-28 | -$36.50M derived: sum of 3 quarters · filed 2020-10-28 | -$36.50M 10-Q · filed 2020-10-28 | -$36.53M 10-K · filed 2017-03-10 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$686.00K derived: sum of 2 quarters · filed 2017-11-08 | -$686.00K 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | -$686.00K 10-Q · filed 2017-08-10 | -$686.00K 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |